LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$89.04 USD
-0.82 (-0.91%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $89.05 +0.01 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$89.04 USD
-0.82 (-0.91%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $89.05 +0.01 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum D VGM
Zacks News
Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EYE vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
EYE vs. LMAT: Which Stock Is the Better Value Option?
Here's Why You Should Add ResMed (RMD) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about ResMed's (RMD) performance.
LeMaitre Vascular (LMAT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 19.05% and 3.56%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Reports Next Week: What to Know Ahead of the Release
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EYE vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. LMAT: Which Stock Is the Better Value Option?
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed's (CHE) performance.
Here's Why You Should Invest in Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edwards Lifesciences' (EW) performance.
Here's Why You Should Add Abbott (ABT) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) on its balanced segmental performances.
Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety
by Zacks Equity Research
Neogen's (NEOG) proprietary testing platform gets upgraded to reduce the incidence of bacterial contamination in livestock.
NuVasive's New TLIF Implant Broadens Spine Surgery Option
by Zacks Equity Research
NuVasive's (NUVA) Modulus TLIF-A is designed to work smoothly with the existing MAS TLIF and MAS Midline access systems.
Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod
by Zacks Equity Research
Boston Scientific's (BSX) Vercise Gevia DBS system should boost neuromodulation revenues for the company.
Myriad Genetics (MYGN) Q4 Earnings Lag Estimates, Revenues Up
by Zacks Equity Research
Myriad Genetics' (MYGN) overall Q4 performance is impressive, excepting weak sales at a few segments.
National Vision (EYE) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
National Vision's (EYE) Military brand registers robust growth while other brands fail to impress.
Haemonetics (HAE) Beats on Q1 Earnings, Raises '19 EPS View
by Zacks Equity Research
Haemonetics (HAE) Q1 performance by all business sections has been impressive, except for BloodCenter.
Moving Average Crossover Alert: LeMaitre Vascular
by Zacks Equity Research
LeMaitre Vascular, Inc. (LMAT) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
LeMaitre Vascular (LMAT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 9.52% and 1.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LeMaitre Vascular (LMAT) Q1 Earnings Miss Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -10.53% and 1.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid
by Zacks Equity Research
Abbott (ABT) reports strong and consistent EPD and Medical Devices performance organically in Q1.
LeMaitre Vascular (LMAT) Q1 Earnings Preview: What's in the Cards?
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LeMaitre Vascular (LMAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LeMaitre Vascular (LMAT) Meets Q3 Earnings Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and -7.28%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Soars to a 52-Week High, Time to Cash Out?
by Zacks Equity Research
LeMaitre Vascular, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LMAT for clues.
LeMaitre Vascular, Inc. (LMAT) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
LeMaitre Vascular, Inc. (LMAT) Sees Hammer Chart Pattern: Time to Buy?